S. Cortés de Miguel , J. Cabeza Barrera , M. Gallardo Medina , L.F. Cassini Gómez de Cádiz , A. Salmerón-García , F. Rodríguez Lucas
{"title":"Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis","authors":"S. Cortés de Miguel , J. Cabeza Barrera , M. Gallardo Medina , L.F. Cassini Gómez de Cádiz , A. Salmerón-García , F. Rodríguez Lucas","doi":"10.1016/S2173-5085(11)70006-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To describe the preparation of topical endotracheal mitomycin C and the clinical outcomes of four patients with recurrent and severe laryngotracheal stenosis (LTS) treated with adjuvant topical mitomycin C.</p></div><div><h3>Method</h3><p>Literature review to determine the concentration and method of preparation of topical mitomycin C for endotracheal use. Review of clinical histories.</p></div><div><h3>Results</h3><p>We established a concentration of 0.4<!--> <!-->mg/ml topical mitomycin C for the treatment of laryngotracheal stenosis. In the treated cases, we applied a 0.4<!--> <!-->mg/ml solution to the wound site following laser surgery and dilatation with bronchoscope. Three patients remain asymptomatic from a respiratory perspective, and treatment failed in one case.</p></div><div><h3>Conclusions</h3><p>LTS treatment is complex due to the continuous development of granulation tissue and fibrosis following injury to the airways. Topical mitomycin C seems to be the ideal adjuvant agent thanks to its powerful antifibrotic effects.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"35 1","pages":"Pages 32-35"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(11)70006-5","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacia Hospitalaria (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173508511700065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Objective
To describe the preparation of topical endotracheal mitomycin C and the clinical outcomes of four patients with recurrent and severe laryngotracheal stenosis (LTS) treated with adjuvant topical mitomycin C.
Method
Literature review to determine the concentration and method of preparation of topical mitomycin C for endotracheal use. Review of clinical histories.
Results
We established a concentration of 0.4 mg/ml topical mitomycin C for the treatment of laryngotracheal stenosis. In the treated cases, we applied a 0.4 mg/ml solution to the wound site following laser surgery and dilatation with bronchoscope. Three patients remain asymptomatic from a respiratory perspective, and treatment failed in one case.
Conclusions
LTS treatment is complex due to the continuous development of granulation tissue and fibrosis following injury to the airways. Topical mitomycin C seems to be the ideal adjuvant agent thanks to its powerful antifibrotic effects.